Vyvgart Iv MG denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for vyvgart iv mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Vyvgart IV for Myasthenia Gravis on Medical-Necessity Grounds

Vyvgart (efgartigimod alfa, intravenous formulation) is FDA-approved for generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody positive. Despite that approval, UnitedHealthcare medical-necessity denials are common for high-cost specialty biologics when the submitted documentation does not explicitly address each criterion in UHC's coverage policy. This is not a reflection of the drug's appropriateness — it is a documentation and process problem that is routinely resolved on appeal.

## Why This Denial Is Appealable

UHC is required to apply coverage criteria that are consistent with recognized standards of care. For a therapy with FDA approval in a serious, potentially life-threatening condition, the bar for overturning a medical-necessity denial is achievable when the clinical record is well-documented and the prescriber's letter directly addresses the plan's specific criteria. The applicable neuromuscular disease guideline organizations' standards are relevant context for the appeal.

## Federal Appeal Framework

• Peer-to-peer review: Request this first. The prescribing neurologist speaking directly with UHC's reviewing physician resolves many medical-necessity denials before formal appeal.
• Internal appeal: Under ACA §2719 and ERISA §503, submit a written appeal within the plan's deadline. Pre-service internal appeals are typically decided within 30 days.
• External review: If the internal appeal is denied, escalate to independent external review within the window on the denial notice (often around four months from the final internal denial).
• Expedited review: Request if the patient's gMG severity — including any bulbar or respiratory involvement — means that standard timelines would create serious health risk.

## Documentation to Gather

1. gMG diagnosis confirmation — neurology records with the clinical findings establishing generalized MG. 2. Anti-AChR antibody documentation — lab results confirming antibody-positive status consistent with the FDA-approved indication. 3. Disease severity and functional impact — objective functional assessments (such as validated MG severity scales used by your neurologist), documentation of activities of daily living impact, and any records of prior MG crisis or hospitalization. 4. Prior treatment history — a chronological record of all prior gMG therapies, with dates, clinical responses, and outcomes, addressing any step-therapy requirements in UHC's policy. 5. Prescriber medical-necessity letter — a detailed letter mapping the patient's clinical profile to each criterion in the UHC coverage policy and the FDA prescribing label. 6. UHC coverage policy — obtain the current version to ensure all criteria are addressed.

## Criteria-Mapping Structure

List each UHC medical-necessity criterion from the current policy alongside the patient-specific chart evidence satisfying it. For any criterion referencing specific clinical thresholds or scores, consult the FDA prescribing label and the current UHC policy for the exact values — never estimate or recall these from memory, as policies are revised regularly.